Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics announces peer-reviewed publication in The Lancet Oncology of pivotal Phase 3 clinical trial data demonstrating that aglatimagene besadenovec (CAN-2409) combined with standard radiotherapy significantly improves disease-free survival by 30% in patients with intermediate- to high-risk localized prostate cancer. The findings suppo…